Glutamate carboxypeptidase II (GCPII, EC 3.4.17.21) is a zinc-dependent exopeptidase and an important therapeutic target for neurodegeneration and prostate cancer. The hydrolysis of N-acetyl-l-aspartyl-l-glutamate (N-Ac-Asp-Glu), the natural dipeptidic substrate of the GCPII, is intimately involved in cellular signaling within the mammalian nervous system, but the exact mechanism of this reaction has not yet been determined. To investigate peptide hydrolysis by GCPII in detail, we constructed a mutant of human GCPII [GCPII(E424A)], in which Glu424, a putative proton shuttle residue, is substituted with alanine. Kinetic analysis of GCPII(E424A) using N-Ac-Asp-Glu as substrate revealed a complete loss of catalytic activity, suggesting the direct involvement of Glu424 in peptide hydrolysis. Additionally, we determined the crystal structure of GCPII(E424A) in complex with N-Ac-Asp-Glu at 1.70 A resolution. The presence of the intact substrate in the GCPII(E424A) binding cavity substantiates our kinetic data and allows a detailed analysis of GCPII/N-Ac-Asp-Glu interactions. The experimental data are complemented by the combined quantum mechanics/molecular mechanics calculations (QM/MM) which enabled us to characterize the transition states, including the associated reaction barriers, and provided detailed information concerning the GCPII reaction mechanism. The best estimate of the reaction barrier was calculated to be DeltaG(++) approximately 22(+/-5) kcal x mol(-1), which is in a good agreement with the experimentally observed reaction rate constant (k(cat) approximately 1 s(-1)). Combined together, our results provide a detailed and consistent picture of the reaction mechanism of this highly interesting enzyme at the atomic level.
Glutamate carboxypeptidase II (n class="Gene">GCPII, EC 3.4.17.21) is a zinc-dependent exopeptidase and an important therapeutic target for neurodegeneration and prostate cancer. The hydrolysis of N-acetyl-l-aspartyl-l-glutamate (N-Ac-Asp-Glu), the natural dipeptidic substrate of the GCPII, is intimately involved in cellular signaling within the mammalian nervous system, but the exact mechanism of this reaction has not yet been determined. To investigate peptide hydrolysis by GCPII in detail, we constructed a mutant of humanGCPII [GCPII(E424A)], in which Glu424, a putative proton shuttle residue, is substituted with alanine. Kinetic analysis of GCPII(E424A) using N-Ac-Asp-Glu as substrate revealed a complete loss of catalytic activity, suggesting the direct involvement of Glu424 in peptide hydrolysis. Additionally, we determined the crystal structure of GCPII(E424A) in complex with N-Ac-Asp-Glu at 1.70 A resolution. The presence of the intact substrate in the GCPII(E424A) binding cavity substantiates our kinetic data and allows a detailed analysis of GCPII/N-Ac-Asp-Glu interactions. The experimental data are complemented by the combined quantum mechanics/molecular mechanics calculations (QM/MM) which enabled us to characterize the transition states, including the associated reaction barriers, and provided detailed information concerning the GCPII reaction mechanism. The best estimate of the reaction barrier was calculated to be DeltaG(++) approximately 22(+/-5) kcal x mol(-1), which is in a good agreement with the experimentally observed reaction rate constant (k(cat) approximately 1 s(-1)). Combined together, our results provide a detailed and consistent picture of the reaction mechanism of this highly interesting enzyme at the atomic level.
Authors: William Desmarais; David L Bienvenue; Krzysztof P Bzymek; Gregory A Petsko; Dagmar Ringe; Richard C Holz Journal: J Biol Inorg Chem Date: 2006-04-05 Impact factor: 3.358
Authors: Cyril Barinka; Markéta Rinnová; Pavel Sácha; Camilo Rojas; Pavel Majer; Barbara S Slusher; Jan Konvalinka Journal: J Neurochem Date: 2002-02 Impact factor: 5.372
Authors: R Gilboa; H M Greenblatt; M Perach; A Spungin-Bialik; U Lessel; G Wohlfahrt; D Schomburg; S Blumberg; G Shoham Journal: Acta Crystallogr D Biol Crystallogr Date: 2000-05
Authors: P Sácha; J Zámecník; C Barinka; K Hlouchová; A Vícha; P Mlcochová; I Hilgert; T Eckschlager; J Konvalinka Journal: Neuroscience Date: 2006-12-05 Impact factor: 3.590
Authors: Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas Journal: World J Surg Date: 2006-04 Impact factor: 3.282
Authors: Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel Journal: J Am Chem Soc Date: 2010-09-15 Impact factor: 15.419
Authors: Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka Journal: FEBS J Date: 2014-06-17 Impact factor: 5.542
Authors: Anna Plechanovová; Youngjoo Byun; Glenda Alquicer; L'ubica Skultétyová; Petra Mlčochová; Adriana Němcová; Hyung-Joon Kim; Michal Navrátil; Ronnie Mease; Jacek Lubkowski; Martin Pomper; Jan Konvalinka; Lubomír Rulíšek; Cyril Bařinka Journal: J Med Chem Date: 2011-10-11 Impact factor: 7.446
Authors: Jan Tykvart; Cyril Bařinka; Michal Svoboda; Václav Navrátil; Radko Souček; Martin Hubálek; Martin Hradilek; Pavel Šácha; Jacek Lubkowski; Jan Konvalinka Journal: J Biol Chem Date: 2015-03-09 Impact factor: 5.157
Authors: Haofan Wang; Youngjoo Byun; Cyril Barinka; Mrudula Pullambhatla; Hyo-Eun C Bhang; James J Fox; Jacek Lubkowski; Ronnie C Mease; Martin G Pomper Journal: Bioorg Med Chem Lett Date: 2009-10-24 Impact factor: 2.823
Authors: Jiri Pavlicek; Jakub Ptacek; Jiri Cerny; Youngjoo Byun; Lubica Skultetyova; Martin G Pomper; Jacek Lubkowski; Cyril Barinka Journal: Bioorg Med Chem Lett Date: 2014-03-28 Impact factor: 2.823